Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based drug developer Idera Pharmaceuticals has reported net loss of $6.28m for the second quarter ended 30 June 2011, compared to $5.3m for the same period in 2010.
Subscribe to our email newsletter
The company’s loss from operations for the second quarter of 2011 was $6.28m, compared to $5.36m for the same period in 2010.
For the six months ended 30 June 2011, the company reported a net loss of $13.13m, compared to $7.24m for the same period in 2010.
Idera Pharma‘s loss from operations was $13.11m for the six months of 2011, compared to $7.1m for the same period in 2010.
Idera Pharma chairman and CEO Sudhir Agrawal said in their autoimmune disease program, they are reviewing the FDA comments on a Phase 2 protocol that they recently submitted to evaluate IMO-3100 in patients with psoriasis, and are assessing next steps to develop IMO-3100 in psoriasis.
"We also look forward to Merck KGaA completing the ongoing Phase 2 trial of IMO-2055 in combination with Erbitux for second-line treatment of head and neck cancer," Agrawal said.